Boston Scientific launches stent study for pancreatic cancer surgery

Boston Scientific ($BSX) enrolled the first patient in a study of its self-expanding WallFlex Biliary RX stent to broaden the indication of the device for the purposes of draining bile before pancreatic cancer surgery. The device is already FDA-approved and CE marked to treat pain and discomfort associated with the disease for up to a year. But WallFlex may also help drain bile from the preoperative area, which can accumulate and lead to complications during the procedure, the company said in a release. The study will include as many as 294 patients. Release

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.